Alembic Pharmaceuticals Limited has announced that CARE Ratings Limited has reaffirmed its credit rating on the company’s Commercial Paper. The rating assigned is CARE A1+, with the action being ‘Reaffirmed’. This reaffirmation pertains to a total amount of Rs. 1,100.00 Crores. The details of this reaffirmation were communicated on June 11, 2026.
Commercial Paper Rating Reaffirmed
Alembic Pharmaceuticals Limited has received confirmation from CARE Ratings Limited regarding the reaffirmation of its credit rating for its Commercial Paper program. The rating stands at CARE A1+, signifying a strong capacity to meet financial obligations. This rating was reaffirmed on June 11, 2026.
Financial Details
The reaffirmation of the CARE A1+ rating applies to a total value of Rs. 1,100.00 Crores. This indicates the company’s continued financial strength and stability in its short-term debt instruments. The rating action undertaken by CARE Ratings reflects their assessment of Alembic Pharmaceuticals’ creditworthiness and its ability to manage its financial commitments effectively.
Source: BSE
